Clinical Trial Detail

NCT ID NCT02788279
Title A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements no
Sponsors Hoffmann-La Roche
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Atezolizumab

Atezolizumab + Cobimetinib

Regorafenib

Age Groups: adult

No variant requirements are available.